Biological testing of
SynAbs 2 and 13. A Binding of
SynAb 2 and bispecific SynAb 13 to HCC1954
(HER2+CD3–) and Jurkat (HER2–CD3+) cells. Flow cytometry histograms representative
of three independent experiments. Cells were incubated with SynAb 2 or bispecific SynAb 13 followed by incubation
with PE-labeled anti-IgG Fc antibody. PE fluorescence was measured
by flow cytometry. B Cytotoxicity assay of SynAb 2 and bispecific SynAb 13. HCC1954 (HER2+CD3–) cells alone or HCC1954/T cell cocultures
(E:T ratio of 10:1) were either not treated or incubated with 500
ng/mL (3.4 nM) SynAb 2 or 500 ng/mL (3.4 nM) bispecific
SynAb 13. HCC1954 viability was assessed by CellTiter-Glo
at 48 h following treatment. Data from three biologically independent
experiments (three different blood donors) with three replicates each. C Cytotoxicity dose–response curve of bispecific SynAb 13. HCC1954/T cell cocultures (E:T ratio of 10:1) were incubated
with varying concentrations of bispecific SynAb 13 (serial
dilutions ranging from 0.005 to 500 ng/mL, 0.034 pM to 3.4 nM). HCC1954
viability was assessed by CellTiter-Glo at 48 h following treatment.
Data from three biologically independent experiments (three different
blood donors) with three replicates each. D Induction
of IFN-γ production by bispecific SynAb 13. T cells
alone, HCC1954 (HER2+CD3–) cells alone,
or HCC1954/T cell cocultures (E:T ratio of 10:1) were either not treated
or treated with 500 ng/mL (3.4 nM) SynAb 2 or 500 ng/mL
(3.4 nM) bispecific SynAb 13. Culture supernatant IFN-γ
was quantified by ELISA at 48 h following treatment. Data from three
biologically independent experiments (three different blood donors)
with three replicates each. Data represented as means + SEM. For statistical
analysis, two-way ANOVA was used followed by posthoc Tukey’s
honestly significant difference multiple comparisons test with multiplicity-adjusted
P values with α = 0.05. ****P < 0.0001.
Curves in C fitted with nonlinear regression model “Sigmoidal,
4PL, X is log(concentration)”.